David Hallal - 20 Dec 2021 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role: Director
Signature: /s/ Adi Osovsky, as Attorney-in-Fact
Issuer symbol: ITOS
Transactions as of: 20 Dec 2021
Net transactions value: -$2,004,000
Form type: 4
Filing time: 22 Dec 2021, 18:59:57 UTC
Previous filing: 22 Jun 2021
Next filing: 25 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ITOS	Common Stock	Options Exercise	$86,000	+20,000		$4.30	20,000	20 Dec 2021	Direct
transaction	ITOS	Common Stock	Options Exercise	$88,500	+30,000	+150%	$2.95^*	50,000	20 Dec 2021	Direct
transaction	ITOS	Common Stock	Sale	$2,178,500	-50,000	-100%	$43.57	0	20 Dec 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ITOS	Stock Option (Right to Buy)	Options Exercise	$0	-20,000	-15%	$0.000000	114,682	20 Dec 2021	Common Stock	20,000	$4.30	Direct	F2
transaction	ITOS	Stock Option (Right to Buy)	Options Exercise	$0	-30,000	-45%	$0.000000	37,039	20 Dec 2021	Common Stock	30,000	$2.95	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.25 to $44.19, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2	One-fourth of the shares subject to the stock option vested on July 1, 2019. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.
F3	One-fourth of the shares subject to the stock option vested on December 5, 2020. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.